β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms-Reference-Cited by-同舟云学术

β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms

Published:2018-10-29 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Xie Wan‑Ying¹,He Ruo‑Hui¹,Zhang Jun²,He Yi‑Jing¹,Wan Zan¹,Zhou Cheng‑Fang¹,Tang Yong‑Jun¹,Li Zhi¹,Mcleod Howard¹,Liu Jie¹

Affiliation:

1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

2. Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic anticancer activity of Sulphoraphane and Teriflunomide co loaded lignin nanoparticles against triple negative breast cancer: Targeted nanoparticle delivery and drug repurposing;Medical Hypotheses;2024-08

2. The multifaceted role of beta‐blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders;The FASEB Journal;2024-07-08

3. Genetic variants in DBC1, SIRT1, UCP2 and ADRB2 as potential biomarkers for severe obesity and metabolic complications;Frontiers in Genetics;2024-05-22

4. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence;European Heart Journal;2024-03-05

5. Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies;Frontiers in Pharmacology;2024-01-09